Top 100 Contractors in NAICS 325412: Pharmaceutical Preparation Manufacturing, Aug 2025–Jul 2026

Parent companies by net contract obligations Aug 1, 2025 – Jul 31, 2026 Code page on GovTribe

The latest 12 months. See the newest fiscal year's list: Top Contractors in NAICS 325412: Pharmaceutical Preparation Manufacturing, FY2025.

The top 10 won 95% of NAICS 325412 contract dollars from August 2025 through July 2026

Ranking facts

Contract obligations
$13,114,408,815 Net of deobligations, by contracts coded NAICS 325412
Contractors
257 Parent companies with an obligation
Largest contractor
Mckesson Corporation $12 billion, 90.0% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV · Free to reuse with credit to GovTribe (CC BY 4.0)

Full ranking

Rank Contractor Net obligations Share Trend
1 $12,015,110,957
Rank history: #1 in FY2021, #2 in FY2022, #1 in FY2023, #1 in FY2024 and #1 in FY2025; unchanged since Aug 2024–Jul 2025.
2 $118,254,297
Rank history: not on the FY2021–FY2024 lists and #5 in FY2025; up 3 since Aug 2024–Jul 2025.
3 $113,641,157
Rank history: not on the FY2021 list, #13 in FY2022, #8 in FY2023, #6 in FY2024 and #26 in FY2025; up 4 since Aug 2024–Jul 2025.
4 $106,483,712
Rank history: not on the FY2021–FY2024 lists and #8 in FY2025; up 4 since Aug 2024–Jul 2025.
5 $65,536,123
Rank history: #16 in FY2021, #14 in FY2022, #7 in FY2023, #7 in FY2024 and #6 in FY2025; up 1 since Aug 2024–Jul 2025.
6 $55,273,060
Rank history: not on the FY2021–FY2023 lists, #8 in FY2024 and #9 in FY2025; new, not ranked in Aug 2024–Jul 2025.
7 $50,162,464
Rank history: not on the FY2021 list, #16 in FY2022, #14 in FY2023, #18 in FY2024 and #13 in FY2025; up 2 since Aug 2024–Jul 2025.
8
Meridian Medical Technologies LLC
$46,041,826
Rank history: not on the FY2021–FY2023 lists, #11 in FY2024 and #11 in FY2025; up 5 since Aug 2024–Jul 2025.
9 $42,247,141
Rank history: not on the FY2021–FY2023 lists, #13 in FY2024 and #12 in FY2025; up 3 since Aug 2024–Jul 2025.
10 $38,863,659
Rank history: not on the FY2021–FY2023 lists, #10 in FY2024 and not on the FY2025 list; new, not ranked in Aug 2024–Jul 2025.
11 $38,563,113
Rank history: not on the FY2021 list, #27 in FY2022, #13 in FY2023, #14 in FY2024 and #14 in FY2025; up 4 since Aug 2024–Jul 2025.
12 $36,255,004
Rank history: not on the FY2021–FY2024 lists and #7 in FY2025; down 2 since Aug 2024–Jul 2025.
13 $33,392,936
Rank history: #21 in FY2021, not on the FY2022–FY2024 lists and #16 in FY2025; new, not ranked in Aug 2024–Jul 2025.
14 $33,119,794
Rank history: not on the FY2021 list, #12 in FY2022, #22 in FY2023, not on the FY2024 list and #4 in FY2025; down 3 since Aug 2024–Jul 2025.
15
Novartis Pharmaceuticals Corporation 2 awardees
$31,536,941
Rank history: not on the FY2021–FY2024 lists and #17 in FY2025; up 2 since Aug 2024–Jul 2025.
16 $29,998,678
Rank history: not on the FY2021–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
17 $25,718,673
Rank history: #23 in FY2021, #24 in FY2022, #11 in FY2023, #16 in FY2024 and #15 in FY2025; down 3 since Aug 2024–Jul 2025.
18
Sagent Pharmaceuticals Inc.
$16,638,758
Rank history: not on the FY2021–FY2024 lists and #18 in FY2025; new, not ranked in Aug 2024–Jul 2025.
19 $16,635,101
Rank history: not on the FY2021–FY2023 lists, #15 in FY2024 and #20 in FY2025; down 3 since Aug 2024–Jul 2025.
20 $15,590,937
Rank history: not on the FY2021–FY2022 lists, #28 in FY2023, not on the FY2024 list and #19 in FY2025; up 114 since Aug 2024–Jul 2025.
21 $11,293,751
Rank history: not on the FY2021–FY2023 lists, #82 in FY2024 and #30 in FY2025; up 41 since Aug 2024–Jul 2025.
22 $9,827,897
Rank history: #5 in FY2021, #5 in FY2022, #43 in FY2023, #31 in FY2024 and #23 in FY2025; up 55 since Aug 2024–Jul 2025.
23 $9,535,684
Rank history: not on the FY2021–FY2024 lists and #25 in FY2025; up 17 since Aug 2024–Jul 2025.
24 $9,412,734
Rank history: not on the FY2021–FY2023 lists, #49 in FY2024 and #21 in FY2025; down 2 since Aug 2024–Jul 2025.
25 $8,700,000
Rank history: not on the FY2021–FY2023 lists, #22 in FY2024 and #24 in FY2025; down 5 since Aug 2024–Jul 2025.
26 $8,497,167
Rank history: #65 in FY2021, #48 in FY2022, #32 in FY2023, #33 in FY2024 and #34 in FY2025; up 8 since Aug 2024–Jul 2025.
27 $8,099,930
Rank history: not on the FY2021 list, #45 in FY2022, not on the FY2023–FY2024 lists and #27 in FY2025; new, not ranked in Aug 2024–Jul 2025.
28 $8,094,273
Rank history: not on the FY2021–FY2025 lists; up 99 since Aug 2024–Jul 2025.
29 $7,615,500
Rank history: not on the FY2021–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
30 $6,962,890
Rank history: not on the FY2021–FY2023 lists, #38 in FY2024 and #29 in FY2025; down 5 since Aug 2024–Jul 2025.
31 $6,080,223
Rank history: not on the FY2021–FY2023 lists, #68 in FY2024 and #40 in FY2025; up 7 since Aug 2024–Jul 2025.
32 $5,236,992
Rank history: not on the FY2021–FY2023 lists, #25 in FY2024 and #37 in FY2025; up 177 since Aug 2024–Jul 2025.
33 $4,974,870
Rank history: not on the FY2021–FY2024 lists and #35 in FY2025; new, not ranked in Aug 2024–Jul 2025.
34 $4,507,247
Rank history: #50 in FY2021, #55 in FY2022, #27 in FY2023, #32 in FY2024 and #33 in FY2025; down 5 since Aug 2024–Jul 2025.
35 $4,415,845
Rank history: #58 in FY2021, #42 in FY2022, #34 in FY2023, #67 in FY2024 and #44 in FY2025; up 187 since Aug 2024–Jul 2025.
36 $4,276,720
Rank history: not on the FY2021–FY2023 lists, #75 in FY2024 and #42 in FY2025; unchanged since Aug 2024–Jul 2025.
37 $3,696,281
Rank history: #31 in FY2021, #38 in FY2022, #18 in FY2023, #30 in FY2024 and #38 in FY2025; down 6 since Aug 2024–Jul 2025.
38 $3,627,452
Rank history: #32 in FY2021, #26 in FY2022, #74 in FY2023, not on the FY2024 list and #43 in FY2025; down 5 since Aug 2024–Jul 2025.
39 $2,945,487
Rank history: not on the FY2021–FY2023 lists, #4 in FY2024 and #41 in FY2025; down 35 since Aug 2024–Jul 2025.
40 $2,891,688
Rank history: not on the FY2021–FY2023 lists, #12 in FY2024 and #87 in FY2025; down 22 since Aug 2024–Jul 2025.
41 $2,651,492
Rank history: not on the FY2021 list, #99 in FY2022, #68 in FY2023, #39 in FY2024 and #46 in FY2025; up 1 since Aug 2024–Jul 2025.
42 $2,468,330
Rank history: #39 in FY2021, #41 in FY2022, #23 in FY2023, #35 in FY2024 and #31 in FY2025; down 15 since Aug 2024–Jul 2025.
43 $2,340,134
Rank history: not on the FY2021–FY2025 lists; up 5 since Aug 2024–Jul 2025.
44 $2,097,799
Rank history: not on the FY2021–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
45 $2,049,579
Rank history: #14 in FY2021, not on the FY2022 list, #83 in FY2023, #99 in FY2024 and #61 in FY2025; up 31 since Aug 2024–Jul 2025.
46 $1,844,468
Rank history: #29 in FY2021, #40 in FY2022, #38 in FY2023, #64 in FY2024 and #56 in FY2025; up 4 since Aug 2024–Jul 2025.
47 $1,826,389
Rank history: not on the FY2021–FY2022 lists, #33 in FY2023, #65 in FY2024 and #52 in FY2025; up 36 since Aug 2024–Jul 2025.
48
American Regent Inc
$1,804,958
Rank history: not on the FY2021–FY2022 lists, #93 in FY2023, #87 in FY2024 and #51 in FY2025; up 39 since Aug 2024–Jul 2025.
49 $1,733,234
Rank history: #44 in FY2021, #1 in FY2022, #2 in FY2023, not on the FY2024 list and #49 in FY2025; new, not ranked in Aug 2024–Jul 2025.
50
Jubilant Hollisterstier LLC 2 awardees, including Jubilant Draximage Inc.
$1,674,707
Rank history: not on the FY2021–FY2024 lists and #64 in FY2025; up 9 since Aug 2024–Jul 2025.
51
Curia Global Inc.
$1,548,154
Rank history: not on the FY2021–FY2022 lists, #59 in FY2023, not on the FY2024 list and #54 in FY2025; up 13 since Aug 2024–Jul 2025.
52 $1,522,263
Rank history: #53 in FY2021, #74 in FY2022, not on the FY2023 list, #63 in FY2024 and #79 in FY2025; up 23 since Aug 2024–Jul 2025.
53 $1,390,565
Rank history: #70 in FY2021, #70 in FY2022, #49 in FY2023, #43 in FY2024 and #72 in FY2025; up 17 since Aug 2024–Jul 2025.
54 $1,257,796
Rank history: #60 in FY2021, #66 in FY2022, #55 in FY2023, #61 in FY2024 and #55 in FY2025; down 5 since Aug 2024–Jul 2025.
55 $1,231,578
Rank history: #35 in FY2021, #62 in FY2022, #45 in FY2023, #83 in FY2024 and #53 in FY2025; down 1 since Aug 2024–Jul 2025.
56 $1,223,169
Rank history: #80 in FY2021, #69 in FY2022, #47 in FY2023, #50 in FY2024 and #94 in FY2025; up 34 since Aug 2024–Jul 2025.
57 $1,105,863
Rank history: not on the FY2021–FY2025 lists; up 79 since Aug 2024–Jul 2025.
58 $1,089,672
Rank history: #56 in FY2021, #43 in FY2022, #37 in FY2023, #53 in FY2024 and not on the FY2025 list; new, not ranked in Aug 2024–Jul 2025.
59 $1,036,397
Rank history: not on the FY2021–FY2024 lists and #73 in FY2025; up 1 since Aug 2024–Jul 2025.
60 $959,715
Rank history: not on the FY2021–FY2022 lists, #81 in FY2023, not on the FY2024 list and #68 in FY2025; up 7 since Aug 2024–Jul 2025.
61
Priority Healthcare Distribution Inc. 2 awardees
$950,394
Rank history: not on the FY2021–FY2023 lists, #59 in FY2024 and #59 in FY2025; down 6 since Aug 2024–Jul 2025.
62
Merz Pharmaceuticals LLC
$853,397
Rank history: not on the FY2021–FY2023 lists, #96 in FY2024 and not on the FY2025 list; up 24 since Aug 2024–Jul 2025.
63 $825,142
Rank history: not on the FY2021–FY2022 lists, #100 in FY2023, not on the FY2024 list and #90 in FY2025; new, not ranked in Aug 2024–Jul 2025.
64 $813,512
Rank history: not on the FY2021–FY2025 lists; up 41 since Aug 2024–Jul 2025.
65 $803,905
Rank history: not on the FY2021–FY2024 lists and #28 in FY2025; down 39 since Aug 2024–Jul 2025.
66 $773,470
Rank history: not on the FY2021–FY2023 lists, #72 in FY2024 and #95 in FY2025; up 35 since Aug 2024–Jul 2025.
67
Astrazeneca Pharmaceuticals LP Through Alexion Pharmaceuticals Inc.
$733,352
Rank history: not on the FY2021–FY2023 lists, #62 in FY2024 and #93 in FY2025; up 32 since Aug 2024–Jul 2025.
68 $715,313
Rank history: not on the FY2021–FY2024 lists and #66 in FY2025; new, not ranked in Aug 2024–Jul 2025.
69 $709,217
Rank history: not on the FY2021–FY2023 lists, #58 in FY2024 and #69 in FY2025; up 3 since Aug 2024–Jul 2025.
70 $700,993
Rank history: #48 in FY2021, #50 in FY2022, #70 in FY2023, #37 in FY2024 and #39 in FY2025; down 35 since Aug 2024–Jul 2025.
71 $674,219
Rank history: not on the FY2021–FY2025 lists; up 59 since Aug 2024–Jul 2025.
72 $558,114
Rank history: #93 in FY2021, #90 in FY2022, #84 in FY2023, not on the FY2024 list and #99 in FY2025; up 92 since Aug 2024–Jul 2025.
73 $553,970
Rank history: not on the FY2021–FY2023 lists, #69 in FY2024 and not on the FY2025 list; up 7 since Aug 2024–Jul 2025.
74 $530,328
Rank history: not on the FY2021–FY2022 lists, #99 in FY2023, not on the FY2024 list and #97 in FY2025; up 49 since Aug 2024–Jul 2025.
75 $526,461
Rank history: #98 in FY2021 and not on the FY2022–FY2025 lists; up 137 since Aug 2024–Jul 2025.
76 $513,180
Rank history: not on the FY2021–FY2024 lists and #77 in FY2025; up 8 since Aug 2024–Jul 2025.
77 $495,100
Rank history: not on the FY2021 list, #92 in FY2022, #41 in FY2023, #45 in FY2024 and not on the FY2025 list; up 23 since Aug 2024–Jul 2025.
78
CSL Behring L.L.C.
$492,045
Rank history: not on the FY2021–FY2025 lists; up 36 since Aug 2024–Jul 2025.
79 $486,480
Rank history: #71 in FY2021, #72 in FY2022, #58 in FY2023, #93 in FY2024 and not on the FY2025 list; up 2 since Aug 2024–Jul 2025.
80 $472,962
Rank history: not on the FY2021–FY2024 lists and #82 in FY2025; down 9 since Aug 2024–Jul 2025.
81 $447,953
Rank history: not on the FY2021–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
82 $440,058
Rank history: not on the FY2021–FY2025 lists; up 36 since Aug 2024–Jul 2025.
83 $401,005
Rank history: not on the FY2021–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
84 $393,759
Rank history: not on the FY2021–FY2025 lists; up 115 since Aug 2024–Jul 2025.
85
Grifols Diagnostic Solutions Inc. Through Grifols USA LLC
$377,947
Rank history: not on the FY2021–FY2025 lists; up 141 since Aug 2024–Jul 2025.
86 $373,721
Rank history: not on the FY2021–FY2025 lists; up 34 since Aug 2024–Jul 2025.
87
Detectachem Inc.
$372,660
Rank history: not on the FY2021–FY2025 lists; up 59 since Aug 2024–Jul 2025.
88 $357,803
Rank history: not on the FY2021–FY2025 lists; up 110 since Aug 2024–Jul 2025.
89 $350,000
Rank history: not on the FY2021–FY2025 lists; up 39 since Aug 2024–Jul 2025.
90
Ucb, Inc.
$339,454
Rank history: not on the FY2021–FY2025 lists; up 17 since Aug 2024–Jul 2025.
91 $337,025
Rank history: not on the FY2021 list, #88 in FY2022, #79 in FY2023, #94 in FY2024 and not on the FY2025 list; up 26 since Aug 2024–Jul 2025.
92
Kiniksa Pharmaceuticals Ltd Through Kiniksa Pharmaceuticals (Uk), Ltd.
$330,119
Rank history: not on the FY2021–FY2025 lists; up 24 since Aug 2024–Jul 2025.
93 $318,917
Rank history: not on the FY2021–FY2025 lists; up 63 since Aug 2024–Jul 2025.
94 $300,000
Rank history: not on the FY2021–FY2022 lists, #86 in FY2023 and not on the FY2024–FY2025 lists; up 103 since Aug 2024–Jul 2025.
95 $289,027
Rank history: #91 in FY2021, #54 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
96 $288,403
Rank history: not on the FY2021–FY2025 lists; up 73 since Aug 2024–Jul 2025.
97 $281,860
Rank history: #3 in FY2021, #3 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
98 $268,660
Rank history: not on the FY2021–FY2025 lists; new, not ranked in Aug 2024–Jul 2025.
99 $253,356
Rank history: not on the FY2021 list, #89 in FY2022, #60 in FY2023, #48 in FY2024 and #50 in FY2025; down 55 since Aug 2024–Jul 2025.
100 $241,160
Rank history: #89 in FY2021, not on the FY2022–FY2024 lists and #96 in FY2025; down 9 since Aug 2024–Jul 2025.
Show 75 more

100 of 257 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $13.4 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. An awardee whose own actions mostly name no parent, and that no other company's actions name as their parent, rolls up its SAM.gov registration's chain of parent companies: it counts under the first company there that other companies' actions name as their parent, or under the parent most of a company's own actions name, whichever comes first; with neither, under the highest company in the chain with federal contracts of its own. Joint ventures stay companies of their own. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Period: the trailing 12 months end with the last month that ended at least 90 days ago, because the Department of Defense reports its contract actions to FPDS about 90 days late. The list is rebuilt each night.
  • Rank changes compare with Aug 2024–Jul 2025. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 NAICS 325412 contractors in Aug 2025–Jul 2026?

1. Mckesson Corporation ($12B), 2. Emergent Biosolutions Inc. ($118M), 3. Phlow Corp. ($114M), 4. Exelan Pharmaceuticals Inc. ($106M), 5. Government of the United States ($65.5M), 6. Nighthawk Biosciences, Inc. ($55.3M), 7. Partner Therapeutics, Inc. ($50.2M), 8. Meridian Medical Technologies LLC ($46M), 9. Teva Pharmaceuticals Usa, Inc. ($42.2M), 10. Roche Holdings Inc. ($38.9M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work